Monday, November 8, 1993
CYTL passes the baton in sepsis
Despite good safety data from a Phase I trial of its CY1787 monoclonal antibody for
sepsis, Cytel Corp. has decided to give the product to its partner, sidestepping for now
the expensive and risky sepsis race.
"I wouldn't be surprised if there were more such decisions," said Jay Kranzler,
president and CEO. Fortunately, the company has enough products in its pipeline to allow
it to be choosy, Kranzler told BioCentury.
Two European safety trials, in nine sepsis patients and in 12 more with allergic rhinitis,
showed that the mouse MAb was well